297 related articles for article (PubMed ID: 35729342)
1. Baseline bone turnover marker levels can predict change in bone mineral density during antiresorptive treatment in osteoporotic patients: the Copenhagen bone turnover marker study.
Bønløkke SE; Rand MS; Haddock B; Arup S; Smith CD; Jensen JEB; Schwarz P; Hovind P; Oturai PS; Jensen LT; Møller S; Eiken P; Rubin KH; Hitz MF; Abrahamsen B; Jørgensen NR
Osteoporos Int; 2022 Oct; 33(10):2155-2164. PubMed ID: 35729342
[TBL] [Abstract][Full Text] [Related]
2. Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate.
Burshell AL; Möricke R; Correa-Rotter R; Chen P; Warner MR; Dalsky GP; Taylor KA; Krege JH
Bone; 2010 Apr; 46(4):935-9. PubMed ID: 20060081
[TBL] [Abstract][Full Text] [Related]
3. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis.
Eastell R; Christiansen C; Grauer A; Kutilek S; Libanati C; McClung MR; Reid IR; Resch H; Siris E; Uebelhart D; Wang A; Weryha G; Cummings SR
J Bone Miner Res; 2011 Mar; 26(3):530-7. PubMed ID: 20839290
[TBL] [Abstract][Full Text] [Related]
4. Bone turnover markers to explain changes in lumbar spine BMD with abaloparatide and teriparatide: results from ACTIVE.
Eastell R; Mitlak BH; Wang Y; Hu M; Fitzpatrick LA; Black DM
Osteoporos Int; 2019 Mar; 30(3):667-673. PubMed ID: 30635696
[TBL] [Abstract][Full Text] [Related]
5. Effects of zoledronic acid on bone mineral density in premenopausal women receiving neoadjuvant or adjuvant therapies for HR+ breast cancer: the ProBONE II study.
Hadji P; Kauka A; Ziller M; Birkholz K; Baier M; Muth M; Bauer M
Osteoporos Int; 2014 Apr; 25(4):1369-78. PubMed ID: 24504100
[TBL] [Abstract][Full Text] [Related]
6. Contribution of bone turnover markers to the variation in bone mineral density: a study in Vietnamese men and women.
Nguyen LT; Nguyen UDT; Nguyen TDT; Ho-Pham LT; Nguyen TV
Osteoporos Int; 2018 Dec; 29(12):2739-2744. PubMed ID: 30196375
[TBL] [Abstract][Full Text] [Related]
7. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
Cosman F; Eriksen EF; Recknor C; Miller PD; Guañabens N; Kasperk C; Papanastasiou P; Readie A; Rao H; Gasser JA; Bucci-Rechtweg C; Boonen S
J Bone Miner Res; 2011 Mar; 26(3):503-11. PubMed ID: 20814967
[TBL] [Abstract][Full Text] [Related]
8. Use of CTX-I and PINP as bone turnover markers: National Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability.
Szulc P; Naylor K; Hoyle NR; Eastell R; Leary ET;
Osteoporos Int; 2017 Sep; 28(9):2541-2556. PubMed ID: 28631236
[TBL] [Abstract][Full Text] [Related]
9. Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study.
Naylor KE; Jacques RM; Paggiosi M; Gossiel F; Peel NF; McCloskey EV; Walsh JS; Eastell R
Osteoporos Int; 2016 Jan; 27(1):21-31. PubMed ID: 25990354
[TBL] [Abstract][Full Text] [Related]
10. Baseline serum PINP level is associated with the increase in hip bone mineral density seen with Romosozumab treatment in previously untreated women with osteoporosis.
Kashii M; Kamatani T; Nagayama Y; Miyama A; Tsuboi H; Ebina K
Osteoporos Int; 2023 Mar; 34(3):563-572. PubMed ID: 36585509
[TBL] [Abstract][Full Text] [Related]
11. Intravenous Zoledronic Acid 5 mg on Bone Turnover Markers and Bone Mineral Density in East China Subjects with Newly Diagnosed Osteoporosis: A 24-month Clinical Study.
Liang BC; Shi ZY; Wang B; Wu P; Kong LC; Yao JL; Li CW; Shi XL
Orthop Surg; 2017 Feb; 9(1):103-109. PubMed ID: 28276638
[TBL] [Abstract][Full Text] [Related]
12. Early changes in biochemical markers of bone turnover and their relationship with bone mineral density changes after 24 months of treatment with teriparatide.
Blumsohn A; Marin F; Nickelsen T; Brixen K; Sigurdsson G; González de la Vera J; Boonen S; Liu-Léage S; Barker C; Eastell R;
Osteoporos Int; 2011 Jun; 22(6):1935-46. PubMed ID: 20938767
[TBL] [Abstract][Full Text] [Related]
13. Reference intervals for serum concentrations of three bone turnover markers for men and women.
Michelsen J; Wallaschofski H; Friedrich N; Spielhagen C; Rettig R; Ittermann T; Nauck M; Hannemann A
Bone; 2013 Dec; 57(2):399-404. PubMed ID: 24076251
[TBL] [Abstract][Full Text] [Related]
14. Teriparatide for idiopathic osteoporosis in premenopausal women: a pilot study.
Cohen A; Stein EM; Recker RR; Lappe JM; Dempster DW; Zhou H; Cremers S; McMahon DJ; Nickolas TL; Müller R; Zwahlen A; Young P; Stubby J; Shane E
J Clin Endocrinol Metab; 2013 May; 98(5):1971-81. PubMed ID: 23543660
[TBL] [Abstract][Full Text] [Related]
15. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover.
Delmas PD; Licata AA; Reginster JY; Crans GG; Chen P; Misurski DA; Wagman RB; Mitlak BH
Bone; 2006 Aug; 39(2):237-43. PubMed ID: 16563890
[TBL] [Abstract][Full Text] [Related]
16. Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers.
Anastasilakis AD; Polyzos SA; Efstathiadou ZA; Savvidis M; Sakellariou GT; Papatheodorou A; Kokkoris P; Makras P
Metabolism; 2015 Oct; 64(10):1291-7. PubMed ID: 26198440
[TBL] [Abstract][Full Text] [Related]
17. Bone Turnover Markers and Bone Mineral Density to Predict Osteoporotic Fractures in Older Women: A Retrospective Comparative Study.
Qu XL; Zheng B; Chen TY; Cao ZR; Qu B; Jiang T
Orthop Surg; 2020 Feb; 12(1):116-123. PubMed ID: 31880071
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of recombinant human parathyroid hormone (1-34) are similar to those of alendronate in the treatment of postmenopausal osteoporosis.
Deng J; Feng Z; Li Y; Pan T; Li Q; Zhao C
Medicine (Baltimore); 2018 Nov; 97(47):e13341. PubMed ID: 30461654
[TBL] [Abstract][Full Text] [Related]
19. Denosumab is effective toward glucocorticoid-induced osteoporosis patients complicated with rheumatic diseases regardless of prior anti-osteoporotic drugs.
Iwamoto N; Okamoto M; Tsuji S; Endo Y; Takatani A; Shimizu T; Umeda M; Fukui S; Sumiyoshi R; Igawa T; Koga T; Kawashiri SY; Aramaki T; Ichinose K; Tamai M; Nakamura H; Origuchi T; Eguchi K; Ueki Y; Kawakami A
J Bone Miner Metab; 2019 May; 37(3):554-562. PubMed ID: 30187273
[TBL] [Abstract][Full Text] [Related]
20. Bone turnover markers are associated with higher cortical porosity, thinner cortices, and larger size of the proximal femur and non-vertebral fractures.
Shigdel R; Osima M; Ahmed LA; Joakimsen RM; Eriksen EF; Zebaze R; Bjørnerem Å
Bone; 2015 Dec; 81():1-6. PubMed ID: 26112819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]